NCT00721734 - Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Multiple MyelomaRenal Insufficiency

Interventions

DRUG

Carfilzomib

Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.

Trial Locations (5)

Cornell University, New York

University of Maryland Medical Center, Baltimore

Barbara Ann Karmanos Cancer Institute, Detroit

Washington University School of Medicine, St Louis

University of California- San Francisco, San Francisco